In a randomised, double-blind study, the efficacy of @entity11822 application in combination with physical therapy to relieve @entity384 was investigated in a cohort of 60 @entity5 @entity1 with secondary @entity4269 , with special reference to the development of the incidence of @entity13171 . All of the @entity1 investigated in this study had @entity281 of the skin. @entity4259 was administered in pharmacological doses. The duration of physical therapy was three weeks. @entity1 were under observation for a further three months. The incidence of @entity13171 among our @entity1 was 11%. During the three-week period of intensive treatment, there was not a single case of @entity13171 in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of @entity13171 in the treatment group, but 50% of the @entity1 in the placebo group exhibited @entity13171 . In spite of higher doses, the @entity4259 level did not rise above normal values. @entity1 under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, @entity4259 was administered. It could be shown, in addition, that by administration of a single high-dose of @entity11822 , @entity32 could be immediately brought under control.

@entity11822 as prophylaxis against @entity13171 in secondary XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity384 :: ('MESH:D002311', 'Disease') :: ['congestion'] @entity4269 :: ('MESH:D008209', 'Disease') :: ['lymphedema'] @entity4259 :: ('MESH:D012643', 'Chemical') :: ['Selenium', 'selenium'] @entity11822 :: ('MESH:D018038', 'Chemical') :: ['sodium selenite'] @entity281 :: ('MESH:D007239', 'Disease') :: ['erysipelas infection'] @entity13171 :: ('MESH:D004886', 'Disease') :: ['erysipelas']
@entity4269 :: (MESH:D008209,Disease) :: ['lymphedema']
